43. Nucl Med Rev Cent East Eur. 2018;21(2):113-114. doi: 10.5603/NMR.a2018.0020. Epub2018 Jun 29.Simultaneous breast cancer and DLBCL lymphoma - role of PET/CT examination with18F-FDG and 18F-FES.Hołody Ł(1), Kunikowska J, Braziewicz J.Author information: (1)Zakład Medycyny Nuklearmej z Ośrodkiem PET Świętokrzyskie Centrum Onkologii,Artwińskiego 3, 25-734 Kielce. lholody1508@gmail.com.Breast cancer is the most common cancer in women in the western world. Theestrogen receptor (ER) is expressed in two thirds of newly diagnosed breastcancers, so hormonal treatment is performed only in the receptor positivepatients. The most successful ER imaging radiopharmaceutical in PET techniques is16α-[18F]-flouro-17β-estradiol (¹⁸F-FES). The diffuse large B cell lymphoma(DLBCL) is one of the most common NHL, however, non-Hodgkin lymphoma constitutes only 4% of all primary cancers in women. The typical staging of disease is doneusing 18-fluorodeoksyglukose (¹⁸F-FDG) PET/CT.DOI: 10.5603/NMR.a2018.0020 PMID: 29956818 